More about High-Yield Cash Accounts with M1
Brokerage Accounts
Retirement Accounts
Other Accounts
Quotes are delayed by 15 minutes.
1D
1W
1M
3M
6M
YTD
1Y
2Y
5Y
ALL
Market cap
$775032579
EPS
-1.4
P/E ratio
--
Price to sales
30.59
Dividend yield
--
Beta
1.40833
Previous close
$9.16
Today's open
$9.19
Day's range
$8.83 - $9.28
52 week range
$8.83 - $25.77
show more
CEO
Markus Warmuth
Employees
150
Headquarters
Boston, MA
Exchange
Nasdaq Global Select
Shares outstanding
85450119
Issue type
Common Stock
Healthcare
Biotechnology & Life Sciences
Monte Rosa Therapeutics: The Market Is Punishing NEK7 For IL-6's Failure
Monte Rosa Therapeutics looks mispriced after ZEUS's failure drove a weak read-through to its differently targeted NEK7 degrader, MRT-8102. Gout offers the nearer value inflection: GEMINI-1 initial clinical data are expected in H2 2027, ahead of cardiovascular outcomes. GLUE's approximately $220 million enterprise value sits below one-quarter of Lilly's $1.2 billion Ventyx deal, despite its pipeline and Novartis partnership.
Seeking Alpha • Nov 17, 2026

Monte Rosa: A Risky Contrarian Buy As Market Abandons Bull Thesis
Monte Rosa Therapeutics, Inc. remains a risky Buy despite nearly 50% share-price losses since my initial recommendation. MRT-8102's promising biomarker data support further study, although ziltivekimab's failure has weakened market confidence in inflammation-targeting cardiovascular drugs. GLUE's roughly $580 million cash balance leaves its pipeline valued at approximately $215 million, but clinical failures and cash burn remain significant risks.
Seeking Alpha • a day ago

Monte Rosa Therapeutics, Inc. (GLUE) Presents at UBS Global Biopharma Conference 2026 Transcript
Monte Rosa Therapeutics, Inc. (GLUE) Presents at UBS Global Biopharma Conference 2026 Transcript
Seeking Alpha • Nov 16, 2026

Monte Rosa Therapeutics Presents Preclinical Data at ACR Convergence 2026 on the Potential of MRT-8102 in Gout
NEK7-directed molecular glue degrader inhibited NLRP3 inflammasome activation in human experimental systems and demonstrated anti-inflammatory activity in a rabbit model of gouty arthritis GEMINI-1, a Phase 2 study of MRT-8102 in patients with gout, is expected to initiate in Q4 2026, with initial data expected in H2 2027 Poster presentation on November 9, 2026, at 10:30 a.m. ET BOSTON, Nov. 09, 2026 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced the presentation of preclinical data showing that MRT-8102, a NEK7-directed MGD, inhibited NLRP3 inflammasome activity in human experimental systems and reduced inflammation in a rabbit model of gouty arthritis, supporting the Company's planned Phase 2 study in patients with gout.
GlobeNewsWire • Nov 9, 2026

Monte Rosa Therapeutics Announces Third Quarter 2026 Financial Results and Business Updates
Positive GFORCE-1 Phase 1 results showed MRT-8102 reduced key pathogenic drivers of atherosclerotic cardiovascular disease (ASCVD) to levels comparable to healthy volunteers across all three dose levels, with treatment-emergent adverse event rates comparable to placebo; Phase 2 initiation in coronary artery disease anticipated in H1 2027 Initiation of Phase 2 study of MRT-8102 in gout expected in Q4 2026, with data update expected in H2 2027; additional Phase 2 initiation in hidradenitis suppurativa anticipated in H1 2027 Initiated MODeFIRe-1 Phase 2 study of MRT-2359 in combination with apalutamide in heavily pretreated metastatic castration-resistant prostate cancer (mCRPC) patients with androgen receptor (AR) mutations; Phase 2 data update expected in 2027; updated Phase 1/2 study data expected this year Novartis initiated Phase 2a/b studies of VAV1-directed MGD MRT-6160 (DDY391) in Sjögren's disease and psoriatic arthritis, triggering a total of $87.5 million in Phase 2 milestone payments to date to Monte Rosa Strong balance sheet with cash, cash equivalents, restricted cash, and marketable securities of $582.6 million (not including MRT-6160 Phase 2 initiation milestones) as of September 30, 2026, expected to support operations into 2029 BOSTON, Nov. 05, 2026 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced business highlights and financial results for the third quarter ended September 30, 2026. “The last quarter marks a tremendously important step forward for our clinical portfolio, with a positive readout from the GFORCE-1 study of MRT-8102, the initiation of Phase 2 development for MRT-2359, and the advancement of our partnered VAV1 program into two Phase 2 studies,” said Markus Warmuth, M.D.
GlobeNewsWire • Nov 5, 2026

Monte Rosa Therapeutics (GLUE) Tops Q3 Earnings and Revenue Estimates
Monte Rosa Therapeutics (GLUE) came out with quarterly earnings of $0.03 per share, beating the Zacks Consensus Estimate of a loss of $0.1 per share. This compares to a loss of $0.33 per share a year ago.
Zacks Investment Research • Nov 5, 2026

Monte Rosa Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BOSTON, Nov. 03, 2026 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced the grant of inducement equity awards to four newly hired non-executive employees as a material inducement to commencing their employment with the Company. The employees received, in the aggregate, non-qualified stock options to purchase 33,775 shares of Monte Rosa Therapeutics common stock, par value $0.0001 per share, with an exercise price per share equal to the closing price of $10.63 as reported by Nasdaq on November 2, the effective date of the grant or the “Grant Date”, which will vest 25% on the first anniversary of the Grant Date and in 36 equal monthly installments thereafter, subject to the employee's continued service with the Company through each applicable vesting date; and restricted stock units for an aggregate of 7,400 shares of Monte Rosa Therapeutics common stock, which will vest 25% on each of the first four anniversaries of the Grant Date, subject to the employee's continued service with the Company through each applicable vesting date, or collectively, the Awards.
GlobeNewsWire • Nov 3, 2026

Wall Street Analysts See a 152.87% Upside in Monte Rosa Therapeutics (GLUE): Can the Stock Really Move This High?
The consensus price target hints at a 152.9% upside potential for Monte Rosa Therapeutics (GLUE). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Zacks Investment Research • Nov 3, 2026

Monte Rosa Therapeutics to Participate in Upcoming Investor Conferences
BOSTON, Nov. 02, 2026 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced that management will participate in the following investor conferences: Guggenheim's 3rd Annual Healthcare Innovation Conference (Boston, MA) – fireside chat, November 9, 2026, at 8:00 a.m. ET UBS Global Biopharma Conference 2026 (London, UK) – fireside chat, November 16, 2026, at 12:00 p.m.
GlobeNewsWire • Nov 2, 2026

Monte Rosa Therapeutics (GLUE) May Report Negative Earnings: Know the Trend Ahead of Q3 Release
Monte Rosa Therapeutics (GLUE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks Investment Research • Oct 29, 2026

¹ Disclosures

Open an M1 investment account to buy and sell Monte Rosa Therapeutics Inc. commission-free¹. Build wealth for the long term using automated trading and transfers.